Introduction
============

Lung cancer is the most common malignancy and the leading cause of cancer-related deaths ([@b1-or-40-02-0783]). Its occurrence and development is a complex process involving oxygen stress, uncontrolled proliferation, apoptosis, cell transformation and inflammation. With the development of molecular biology, immunotherapy and molecular targeted therapy, significant breakthroughs in the molecular mechanisms of lung cancer have been achieved in recent years. A better understanding of the molecular mechanisms of lung cancer may provide an effective way of improving the prevention, diagnosis, treatment and prognosis of patients with lung cancer.

In clinical diagnosis, pathologists often assess the tumor grade based on the morphology of the nucleus. Components of the nuclear envelope have essential roles in many aspects of cell function and may be involved in tumor development and progression. A series of protein-protein interactions take place on the nuclear envelope which affect tumor cell biology ([@b2-or-40-02-0783]). The linker of nucleoskeleton and cytoskeleton (LINC) complex has been suggested to anchor both the nuclear membranes and nuclear lamina to the cytoskeleton ([@b3-or-40-02-0783]--[@b5-or-40-02-0783]). The KASH domain of the Nesprin family of proteins and the SUN domain of the SUN family of proteins interact in the perinuclear space, and play a major role in the LINC complex ([@b5-or-40-02-0783]--[@b8-or-40-02-0783]). The SUN family of proteins which are anchored on the inner nuclear membrane connect with the lamina and chromosomes, and the Nesprin family of proteins positioned on the outer nuclear membrane connect with the cytoskeleton proteins ([@b9-or-40-02-0783],[@b10-or-40-02-0783]). The LINC complex functions in neurogenesis, gametogenesis and retina formation, and LINC defects may contribute to human diseases, such as muscular dystrophy, ataxia, and cancer ([@b11-or-40-02-0783],[@b12-or-40-02-0783]).

Some LINC complex proteins have been reported to be specifically expressed in tumors. The methylation of Nesprin1 gene promoter may be associated with the development of lung cancer ([@b13-or-40-02-0783],[@b14-or-40-02-0783]). SUN1 and 2 are expressed at low levels in breast cancer ([@b15-or-40-02-0783]). Lv *et al* demonstrated that SUN2 plays a tumor-suppressor role by suppressing the Warburg effect in lung cancer ([@b16-or-40-02-0783]). Sperm-associated antigen 4 (SPAG4), first found in mammalian sperm tails, belongs to the SUN family of proteins, interacts specifically with the outer dense fiber 27 (ODF27) protein ([@b17-or-40-02-0783]), and plays important roles in spermatogenesis and sperm motility. SPAG4 is localized in the inner nuclear membrane and is a mediating protein between the nucleoskeleton and cytoskeleton. Recently, Kennedy *et al* reported that SPAG4 may be an independent cancer marker ([@b12-or-40-02-0783]). Knaup *et al* revealed that SPAG4, an HIF1 target, was correlated with the prognosis of renal cell carcinoma ([@b18-or-40-02-0783]). From these findings, we speculated that SPAG4 may be associated with the development of lung cancer.

In the present study, we examined clinical samples of lung cancer and found that SPAG4 was highly expressed. To determine the possible mechanism of SPAG4 action in lung cancer, experiments were designed to reveal that SPAG4 interacts with Nesprin3, which influences the migration of lung tumor cells. This SPAG4/Nesprin3 interaction may offer new strategies for the diagnosis and treatment of lung cancer.

Materials and methods
=====================

### Collection of tissue samples

This study was approved in December 2014 by the Ethics Committee of the Third Xiangya Hospital, Central South University, Changsha, China, and the collection of lung cancer samples was performed in accordance with ethical standards. The signing of the informed consent form was carried out by the members of the test group and the subjects. When the informed consent was signed, the subject was informed about the details of the clinical trial. None of the patients had undergone preoperative intervention therapy or chemotherapy. The tissues were removed during surgery, and those used for western blotting were immediately stored in liquid nitrogen, and those used for immunohistochemistry were stored in 10% formalin at room temperature. Paired samples of lung cancerous and paracarcinomatous tissues for immunohistochemistry were obtained from 46 patients with lung cancer who underwent lung lobectomy from December 2014 to June 2015 at the Department of Cardiothoracic Surgery, Third Xiangya Hospital of Central South University, Changsha, China. Sixteen of the 46 paired samples were also used for western blotting. The adjacent tissues were obtained from the edge of the lung lobe (≥5 cm from the carcinoma). These 46 patients included 29 males and 17 females with a mean age of 57.5 years (range, 32--74 years). No distant metastasis was found in the selected patients before surgery. Detailed clinicopathological data such as tumor size, clinical grade \[according to tumor-node-metastasis (TNM) stage\], histological type, differentiation degree and lymph node metastasis were obtained and summarized. The tumor stage was defined according to the 8th edition of the TNM classification of the Union for International Cancer Control (UICC).

### Construction of plasmids

The eukaryotic vector pEGFP-N1 carrying different fragments of *SPAG4* was used, and each of these fragments was amplified by polymerase chain reaction (PCR) using the following primers: forward, 5′-CC[AAGCTT]{.ul}GCCACCAGGATGCGGCGAAGCTCCCG-3′ (the *Hind*III site was included) and reverse, 5′-GG[GTCGAC]{.ul}AAATGGGGCCCCTGTGCACTG-3′ (the *Sal*I site was included) for integral SPAG4; forward, 5′-CC[AAGCTT]{.ul}GCCACCAGGATGCGGCGAAGCTCCCG-3′ (*Hind*III) and reverse, 5′-GC[GTCGAC]{.ul}CGGATGGAACAGACCTCCCT-3′ (*Sal*I) for the 1--165 amino acid (aa) fragment of SPAG4; forward, 5′-GC[AAGCTT]{.ul}ATGCCTCCCCCGCGGGTGTTCAAG-3′ (*Hind*IIId) and reverse, 5′-GG[GTCGAC]{.ul}GCATAGTCGGGCTTCCGCAC-3′ (*Sal*I) for the 126--260aa fragment of SPAG4; forward, 5′-GC[AAGCTT]{.ul}ATGGATTTTGTGCGGAAGCCCGAC-3′ (*Hind*III) and reverse, 5′-GG[GTCGAC]{.ul}AAATGGGGCCCCTGTGCACTG-3′ (*Sal*I) for the 232--438aa fragment of SPAG4.

The eukaryotic vector pCMV-C-flag was used to construct the tagged expression plasmid pCMV-C-flag-SPAG4: forward, 5′-CC[AAGCTT]{.ul}GCCACCAGGATGCGGCGAAGCTCCCG-3′ (the *Hind*III site was included) and reverse, 5′-GC[CTCGAG]{.ul}ATGGGGCCCCTGTGCACTGC-3′ (the *Xho*I site was included). The eukaryotic vector pCMV-N-HA was used to construct pCMV-N-HA-Nesprin3: forward, 5′-CAT[AAGCT]{.ul}TATGAACTCAGCAGCCCCAGGAC-3′ (the *Hind*III site was included) and reverse, 5′-G[GGATCC]{.ul}ATCCTCCAAAAATCGGAT-3′ (the *Kpn*I site was included). The products were sequenced to confirm the identity. The procedure and conditions for PCR were: 95°C for 2 min and 30 sec, followed by 35 cycles at 94°C for 30 sec, 62°C for 30 sec, and 72°C for 1 min and 20 sec, and a final extension at 72°C for 10 min. All finished vectors were sent to Sangon Biotech Co., Ltd. (Shanghai, China) for gene sequencing.

### Cell culture and electric transfection methods

The lung cancer cell line A549 was purchased from the Xiangya Cell Bank, Central South University, Changsha, China. RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (FBS) was used for cell culture. For electric transfection, the cells were diluted with electric transfection buffer (Eppendorf, Hamburg, Germany) at 0.5--1.5×10^6^ cells/ml, mixed with plasmids 20--30 µg/ml, and then placed in electric transfection dishes. The cell dishes were installed on a Multiporator (Eppendorf Electroporator 2510), with the parameters set at 600 V and 100 µsec. The transferred cells were cultured in normal medium at 37°C in a 5% CO~2~ and 95% humidified air atmosphere. After 20 h, the cells were observed under a fluorescence microscope and images were obtained.

### Bimolecular fluorescence complementation (BiFC) assay

To construct recombinant BiFC plasmids, the Nesprin3 and SPAG4 cDNA sequences were respectively amplified (from A549 total mRNA) by PCR using the following primers: forward, 5′-CC[AAGCTT]{.ul}GCCACCAGGATGCGGCGAAGCTCCCG-3′ (the *Hind*III site was included) and reverse, 5′-CC[GGTACC]{.ul}ATGGGGCCCCTGTGCACTGCCCTC-3′ (*Kpn*I) for SPAG4; forward, 5′-CAT[AAGCT]{.ul}TATGAACTCAGCAGCCCCAGGAC-3′ (*Hind*III) and reverse, 5′-G[GGATCC]{.ul}ATCCTCCAAAAATCGGAT-3′ (*Kpn*I) for Nesprin3. Fragments of YFP DNA sequence from the PA7-YFP vector were truncated at residue 155, and were thus designated as YN and YC DNA fragments, using the following primers: forward, 5-′CGG[GGTACC]{.ul}CGCTCCATCGCCACGATGGTGAGCAAGGGCGAG-3′ (*Kpn*I was included) and reverse, 5′-CCG[GAATTC]{.ul}TTAGGCCATGATATAGACGTTGT-3′ (*Eco*RI) for YN; forward, 5′-CGG[GGTACC]{.ul}CGCCCGGCCTGCAAGATCCCGAACGACCTGAAACAGAAGGTCATGAACCACGACAAGCAGAAGAACGGCAT-3′ (*Kpn*I) and reverse, 5′-CCG[GAATTC]{.ul}TTACTTGTACAGCTCGTCCATGC-3′ (*Eco*RI) for YC. The YN DNA fragment was connected to the 3′ (C-terminus) of Nesprin3 cDNA, and the YC fragment was connected to the 3′ (C-terminus) of SPAG4 cDNA. The connected fragments were inserted into the pcDNA3.1(+) vector to generate pcDNA3.1(+)-Nesprin3-YN and pcDNA3.1(+)-SPAG4-YC, respectively. All constructs were verified by sequencing (Sangon Biotech Co., Ltd.).

For the BiFC assay, the cells were suspended in 300 µl transfer buffer (Eppendorf) and co-transfected with a mixture of pcDNA3.1(+)-Nesprin3-YN and pcDNA3.1(+)-SPAG4-YC using the electroporation method. Cells were maintained in a 5% CO~2~ and 95% humidified air atmosphere at 37°C for 20 h. Finally, the cells were analyzed using a fluorescence microscope (Nikon Corp., Melville, NY, USA).

### Establishment of the SPAG4 and Nesprin3 silenced A549 cell model

The GV248 lentiviral vector (containing neomycin resistant and EGFP genes; Shanghai GeneChem, Co., Ltd., Shanghai, China) carrying three types of SPAG4-shRNA or three types of Nesprin3-shRNA was used to screen for maximum silencing efficiency. We electrically transfected the SPAG4-shRNA or Nesprin3-shRNA vectors into A549 cells to construct the SPAG4/Nesprin3-silenced A549 cell model, and the analogue vector was used as the control. Twenty hours after electric transfection, the A549 cells were cultured in medium with neomycin (1 mg/ml) for 9 days (5--7 days after all cells in the untransfected group died). Each cell line was then subjected to extensive culture. SPAG4 or Nesprin3 expression was determined for each group using western blotting.

### Western blotting

Tissues or cells were lysed in radioimmunoprecipitation assay (RIPA; Beyotime Institute of Biotechnology, Haimen, China) buffer with protease inhibitors (cOmplete Mini; Roche Diagnostics, Basel, Switzerland) and phenylmethanesulfonyl fluoride (PMSF) (KGP610; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). After electrophoresis, the proteins were transferred to polyvinylidene fluoride (PVDF) membranes (IPVH10010; EMD Millipore, Billerica, MA, USA). The Bio-Rad electrophoresis system and Wet blotting system (both from Bio-Rad Laboratories, Inc., Hercules, CA, USA) were used to perform the aforementioned steps. Non-specific binding was blocked by immersing the membrane in 5% non-fat milk for 2 h at room temperature with shaking. Primary antibodies were applied overnight at 4°C. The rabbit anti-SPAG4 antibody (cat. no. sc-135414; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used at a 1:500 dilution, the rabbit anti-Nesprin3 antibody (cat. no. ab74261; Abcam, Cambridge, UK) was used at a 1:1,000 dilution, the mouse anti-Flag antibody (cat. no. AF519; Beyotime Institute of Biotechnology), the mouse HA-Tag antibody (cat. no. 66006-1-1g) and mouse anti-GAPDH antibody (cat. no. 60001-1-1g) (both from ProteinTech Group, Inc.: Wuhan Sanying Biotechnology, Wuhan, China) were used at a 1:2,000 dilution. Horseradish peroxidase-conjugated anti-mouse (cat. no. 7076s) or anti-rabbit secondary antibodies (cat. no. 7074s) (both from Cell Signaling Technology, Inc., Danvers, MA, USA) were applied at 1:3,000 for 1 h at 37°C. Signals were visualized using an enhanced chemiluminescent (ECL) system. Protein band intensity was measured and normalized to GAPDH by ImageJ software.

### Immunohistochemical staining

Immunohistochemical staining for the SPAG4 protein was carried out using an SP ready-to-use kit (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.: OriGene Technologies, Beijing, China) according to the manufacturer\'s instructions. The rabbit anti-hSPAG4 antibody was used as the primary antibody according to the manufacturer\'s instructions. The SPAG4 antibody was diluted at 1:50. Sections were then incubated with biotin-labeled goat anti-rabbit/mouse IgG (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.: OriGene Technologies) for 10 min and subsequently with streptavidin peroxidase for 10 min. The slides were visualized using diaminobenzidine and counterstained with hematoxylin before microscopy. Addition of the primary rabbit anti-SPAG4 antibody was omitted from the protocols for the negative controls.

Three random ×200 microscopic fields containing tumor cells were evaluated by two independent experienced investigators without prior knowledge of the patient disease data; ≥100 tumor cells were examined per field. Two scoring systems including staining intensity and percentage of immunoreactive cells were used. The staining intensity was scored on a semi-quantitative 4-point scale: 0, negative control; 1, weak cytoplasmic and nuclear staining (slightly darker than the negative control); 2, moderate staining; and 3, intense staining (equivalent to or darker than the positive control). The percentage of stained cells was also scored on a semiquantitative 4-point scale: 0 for \<10%, 1 for 10--25%, 2 for 25--50%, and 3 for \>50%. Finally, the scores of staining intensity and the percentage of stained cells were combined and evaluated as follows: 0--1 as -, 2 as +, 3--4 as ++ and 5--6 as +++.

### Co-immunoprecipitation (Co-IP)

Protein (200 µg) extracted from the transfected cells, 30 µl sepharose beads (Santa Cruz Biotechnology, Inc.) and cell lysates \[treated with 1 mM DL-dithiothreitol (DTT), 1 mM PMSF, 1 µg/ml aprotinin, l µg/ml leupeptin protease inhibitor, 0.5% NP40\] were mixed to a volume of 400 µl. The cell lysates obtained from the cells were precleared by incubation for 2 h at 4°C on a shaker. The clear supernatant was incubated overnight with control IgG, anti-HA (cat. no. 66006-1-1g; ProteinTech Group, Inc.: Wuhan Sanying Biotechnology) or anti-FLAG antibody (AF519; Beyotime Institute of Biotechnology). The samples were then washed with 0.5% NP40 cell lysate three times. Immobilized protein complexes were eluted by denaturation in 2X SDS sample buffer at 95°C for 10 min for subsequent western blotting.

### Immunofluorescence

For immunofluorescence, the cells were washed with phosphate-buffered saline (PBS) solution (4°C) and immediately fixed in cold methanol for 15 min and permeabilized for 10 min in 0.2% Triton X-100 (Beyotime Institute of Biotechnology). Staining antibodies included mouse anti-Nesprin3 at a 1:200 dilution and rabbit anti-SPAG4 at a 1:100 dilution. After washing, the sections were incubated with Cy3-labeled goat anti-rabbit IgG (cat. no. KGAB019; Nanjing KeyGen Biotech Co., Ltd.). Nuclei were counterstained using DAPI (Invitrogen: Thermo Fisher Scientific, Inc., Carlsbad, CA, USA). After staining, the cells were imaged on a Nikon TE300 Eclipse inverted microscope (Nikon Corp.).

### Statistical analysis

Statistical analyses were carried out using SPSS version 24.0. Analysis of the association between the expression of SPAG4 and clinicopathological features was performed using Pearson\'s Chi-square test or Fisher\'s exact test. All values from the *in vitro* assays were expressed as the mean ± SEM or SD of at least three independent experiments or replicates. P\<0.05 was considered statistically significant in all tests.

Results
=======

### Increased expression of SPAG4 in lung cancer tissue

[Fig. 1A](#f1-or-40-02-0783){ref-type="fig"} shows the specificity of the anti-SPAG4 antibody. No non-specific bands were detected and the antibody was qualified for immunohistochemistry studies. [Fig. 1B and C](#f1-or-40-02-0783){ref-type="fig"} reveals the high SPAG4 expression in lung carcinoma tissues. Based on the assessment by pathologists, SPAG4 expression as revealed by immunohistochemistry was divided into four levels. The cancer and paracancerous tissue sampling areas are shown in [Fig. 2A and B](#f2-or-40-02-0783){ref-type="fig"}, respectively. The staining of the SPAG4 protein was predominantly localized in the cytoplasm of lung cancer cells. Precise localization of SPAG4 is shown in the immunofluorescence results. The positive rate of SPAG4 expression in cancerous tissues was 69.6% (32/46), and only 21.7% (10/46) in the corresponding adjacent non-cancerous tissues ([Table I](#tI-or-40-02-0783){ref-type="table"}). The ratio of SPAG4 positivity was significantly different between the cancerous and adjacent tissues (P\<0.001).

Notably, according to these data, SPAG4 expression was not significantly correlated with age, histological type or tumor size, but was strongly correlated with tumor differentiation grade (P=0.014), lymph node metastasis (P=0.035) and clinical stage (P=0.008) ([Table II](#tII-or-40-02-0783){ref-type="table"}). These results indicated that SPAG4 was upregulated in lung cancer and its high expression was closely related to tumor cell migration in lung cancer.

### SPAG4 promotes the migration of lung cancer cells

Given that SPAG4 expression was upregulated in lung cancer tissues, we then determined whether SPAG4 was involved in regulating the biological behavior of lung cancer cells. Marked downregulation of SPAG4 expression was observed in SPAG4-RNAi-treated A549 cells ([Fig. 3A](#f3-or-40-02-0783){ref-type="fig"}). Immunofluorescence further demonstrated an evident reduction in SPAG4 expression in SPAG4-RNAi-treated A549 cells, demonstrating that the expression of SPAG4 was successfully reduced by the RNAi method ([Fig. 3B](#f3-or-40-02-0783){ref-type="fig"}).

As shown in [Table II](#tII-or-40-02-0783){ref-type="table"}, SPAG4 may be closely associated with tumor cell migration. The scratch wound assay revealed that cell migration of SPAG4-silenced cells was slower than that of the control ([Fig. 3C and D](#f3-or-40-02-0783){ref-type="fig"}). These results indicated that SPAG4 plays an important role in the migration of lung cancer cells, and a higher level of SPAG4 expression is highly related to stronger migration of cancer cells.

### Transmembrane helix plays a major role in SPAG4 positioning

To determine the location of SPAG4 protein in lung cancer cells, we generated the pEGFP-N1-SPAG4 plasmid encoding the SPAG4-GFP fusion protein, and then a series of GFP-SPAG4 deletion mutants were generated to identify the region that is critical for localization of SPAG4 to the nuclear envelope or cytoplasm. According to the gene information in NCBI ([Fig. 4A](#f4-or-40-02-0783){ref-type="fig"}), we constructed the full-length and three fragments of SPAG4 into the pEGFP-N1 plasmid, respectively. Each of the four plasmids was transfected into A549 cells, and confocal laser scanning microscopy was used to obtain images ([Fig. 4B](#f4-or-40-02-0783){ref-type="fig"}). The green fluorescence from the full-length SPAG4-transfected cells was located evenly around the nucleus and on one side of the nucleus in the cytoplasm, while the fragment 1-165aa was located in the cytoplasm and not on the nuclear membrane. The fragment 126-260aa, containing the transmembrane helices and the coiled-coil region, was positioned in the membrane structure of the cells. However, its agglomeration was not only on one side of the nucleus but also occurred elsewhere in the cytoplasm. The fragment 232-438aa, containing only the SUN domain, was not only located in the membrane structure, but also on one side of the nucleus in the cytoplasm. It is evident that the C-terminus (SUN domain) of SPAG4 most probably guides it to the nuclear envelope, while the transmembrane helices help it anchor on the inner nuclear envelope.

### Identification of Nesprin3 as an interacting protein of SPAG4

Since it has long been known that Nesprin3 silencing greatly attenuates the migratory flow response with cells moving significantly more slowly in the direction of flow ([@b19-or-40-02-0783]), we suspected that SPAG4 may be closely related to Nesprin3, which is located on the outer nuclear membrane and is also a component of the LINC complex.

The Co-IP assay was used to successfully confirm the interaction between SPAG4 and Nesprin3 ([Fig. 5A](#f5-or-40-02-0783){ref-type="fig"}). Following co-transfection with the pCMV-C-flag-SPAG4 and pCMV-N-HA-Nesprin3 vectors, the cell lysates were subjected to the Co-IP assay. In addition, we consolidated this conclusion using the BiFC assay ([@b20-or-40-02-0783]). Cells were co-transfected with pcDNA3.1-SPAG4-YC and pcDNA3.1-Nesprin3-YN, and the yellow image around the nuclear envelope indicated the interaction between SPAG4 and Nesprin3 ([Fig. 5B](#f5-or-40-02-0783){ref-type="fig"}).

### SPAG4 exerts migration-promoting functions by regulating Nesprin3 in lung cancer

The interaction between SPAG4 and Nesprin3 was further confirmed by the distribution of Nesprin3 ([Fig. 6A](#f6-or-40-02-0783){ref-type="fig"}). Immunofluorescence staining revealed that Nesprin3 exhibited strong nuclear membrane localization in A549 cells. When SPAG4 was silenced, Nesprin3 was not completely distributed around the nuclear membrane, and its expression appeared to decrease. As shown in [Fig. 6B and C](#f6-or-40-02-0783){ref-type="fig"}, SPAG4 silencing significantly reduced the expression of Nesprin3.

It appears that SPAG4 affects the migration of lung cancer cells by regulating Nesprin3. Thus, we studied the effect of Nesprin3 on the migration of lung cancer cells. We performed the scratch wound assay, and found that Nesprin3-silenced A549 cells (verified by western blotting as shown in [Fig. 7A](#f7-or-40-02-0783){ref-type="fig"}) had slower migration, and exhibited the same trend as SPAG4 ([Fig. 7B and C](#f7-or-40-02-0783){ref-type="fig"}). These results indicated that SPAG4, acting as a positive regulator of Nesprin3, promoted cell migration in lung carcinoma.

Discussion
==========

SPAG4 is a new potential tumor biomarker, and was found to be significantly increased in lung carcinoma tissues. The present study indicated that downregulation of SPAG4 expression suppressed cell migration. In addition, we validated the interaction between SPAG4 and Nesprin3, and the role of Nesprin3 in migration conformed with the possible link between the two proteins. We found that SPAG4 may regulate the localization and expression of Nesprin3 at the protein level and further promote the development of lung cancer. This SPAG4/Nesprin3 axis may be useful for the development of new treatment strategies for patients with lung cancer. In the present study, we focused on the following aspects to determine the relationship between SPAG4, Nesprin3 and lung cancer.

Firstly, nuclear heteromorphism is an important index in determining the degree of tumor differentiation ([@b2-or-40-02-0783]). The downregulation of SUN2, Nesprin1 and 2 may render the nucleus easy to deform; thus worsening the tumor cell differentiation ([@b21-or-40-02-0783]). Previous studies have revealed that LINC complex proteins may regulate the proliferation and migration of cancer cells, and that Nesprin1 and 2 affect cell proliferation ([@b15-or-40-02-0783]). In addition, Nesprin3 expression is required for flow-induced MTOC polarization and directional migration ([@b19-or-40-02-0783]), and SUN2 inhibits tumor cell proliferation and migration ([@b16-or-40-02-0783]). Although the expression of many LINC complex proteins is downregulated in cancer, SPAG4 was found to be upregulated in renal carcinoma ([@b18-or-40-02-0783]). We found that the expression of SPAG4 was significantly higher in pulmonary carcinoma than in adjacent tissues. In addition, the results of immunohistochemistry revealed that SPAG4 expression was associated with tumor differentiation grade. Thus, SPAG4 may serve as a new biomarker for lung cancer diagnosis.

Secondly, the LINC complex plays a significant role in cell growth, such as cell migration, nuclear positioning, and the cell cycle ([@b22-or-40-02-0783]). Knaup *et al* indicated that SPAG4 overexpression promoted cell proliferation ([@b18-or-40-02-0783]), and our results from the scratch wound assay revealed that SPAG4 silencing inhibited the migration of cancer cells. These findings demonstrated that SPAG4 acts as a facilitator in tumor progression. Shoji *et al* revealed that the knockdown of SPAG4 led to tetraploidy of cancer cells, resulting in subsequent suppression of cell proliferation due to cell division disturbance ([@b23-or-40-02-0783]). In the present study, we provided evidence to demonstrate that SPAG4 is a positive regulator of Nesprin3. Nesprin3, an outer nuclear membrane protein, has been reported to influence the directional migration of cells ([@b19-or-40-02-0783]) and was revealed to play an important role in promoting cell migration in our study. We also examined the distribution and structure of SPAG4, and observed that SPAG4 can anchor to the inner nuclear envelope and is polarized in the cytoplasm. The SUN domain cannot be folded correctly without transmembrane helices, and may be found in the endoplasmic reticulum first, and then anchored to the inner nuclear envelope by transmembrane helices.

Thirdly, the LINC complex is known to be the link between the nuclear skeleton and cytoplasmic skeleton. The KASH and SUN family of proteins have a variety of functions in the LINC complex ([@b24-or-40-02-0783]). While Nesprin1 and 2 are related to actin filaments and Nesprin4 connects to microtubules, Nesprin3 is closely related to MTOC ([@b11-or-40-02-0783]). The MTOC/nucleus connectivity affects a series of cell functions including migration. It has been reported that Nesprin3 has a structural role by organizing perinuclear cytoskeletal architecture as well as a functional role by modulating flow-induced MTOC migration ([@b19-or-40-02-0783],[@b25-or-40-02-0783]). These results reveal the possible relationship between SPAG4 and Nesprin3. We confirmed the interaction between SPAG4 and Nesprin3 by immunoprecipitation and BiFC assays. The silencing of SPAG4 resulted in the loose localization of Nesprin3 and a decrease in Nesprin3 expression. Therefore, we suggest that the roles of SPAG4 and Nesprin3 in cell migration are synergistic. Previous studies have revealed that Nesprin3 silencing reduces both the cell migration velocity and the directionality of migration ([@b19-or-40-02-0783]). The scratch wound assay with Nesprin3-silenced cancer cells supports this view. Without the link between SPAG4 and Nesprin3, the MTOC/nuclear connectivity may be weakened and chromosomes may move slowly, further reducing the migration of lung cancer cells.

To maintain the core function of the LINC complex in connecting the genome and nucleoskeleton to cytoplasmic filaments and the extracellular matrix, the molecular structure of the SUN-KASH interface would need to provide a tight binding interface impervious to disruption ([@b26-or-40-02-0783]). The loss of these nuclear membrane proteins leads to an incomplete nuclear membrane structure. Therefore, since a series of LINC complex proteins such as SUN2 and Nesprin2 are downregulated in tumors ([@b13-or-40-02-0783],[@b15-or-40-02-0783],[@b16-or-40-02-0783]), we speculate that SPAG4/Nesprin3 complexes may increase compensatorily in order to complement missing LINC complexes to maintain the total number of LINC complexes. It is possible that tumor cells have alternative and cross-coordinated mechanisms to maintain the characteristics of high invasion, once one becomes deficient, the other compensates for the lack of activity.

Finally, although this interaction was confirmed, the exact relationship between SPAG4 upregulation and the downregulation of other LINC complex proteins is still unclear. We did not determine the relationship between SPAG4 expression and the prognosis of lung cancer patients. In addition, whether the SPAG4/Nesprin3 complex complements the decreasing LINC complex in lung cancer requires further validation. Such knowledge will, in turn, provide a theoretical basis for new strategies in lung cancer diagnosis and treatment.
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![Western blotting of SPAG4 expression in lung carcinoma. (A) Validation of anti-SPAG4 antibody specificity. The lysates of A549 cells (lane 2) and lysis buffer with no protein (blank control, lane 3) were subjected to western blotting with an anti-SPAG4 antibody. (B) Western blotting revealed that SPAG4 was highly expressed in 16 pairs of lung carcinoma tissues. In each case, the left is from lung carcinoma tissue, the right is from adjacent tissue. GAPDH was used as an internal control. (C) The statistical results based on SPAG4 relative expression. Box plots correspond to the mean ± SD, and the P-value was calculated using the Student\'s t-test. \*\*P\<0.01. SPAG4, sperm-associated antigen 4.](OR-40-02-0783-g00){#f1-or-40-02-0783}

![IHC staining of SPAG4 in lung carcinoma tissues. (A) Representative IHC staining of SPAG4 in non-cancerous lung tissues. The sample on the left is negative, and the sample on the right is positive. (B) Representative IHC staining of SPAG4 in lung carcinoma tissues. IHC results were divided into four categories. The basis and method of classification can be found in Materials and methods. SPAG4, sperm-associated antigen 4; IHC, immunohistochemical.](OR-40-02-0783-g01){#f2-or-40-02-0783}

![Effects of SPAG4 gene silencing in A549 cells. (A) Western blotting revealed that the SPAG4 gene was successfully silenced by SPAG4-RNAi. (B) Using Cy3 red fluorescence-labeled SPAG4 antibody, SPAG4-silenced cells did not exhibit red fluorescence. (C and D) Scratch wound assay. The images in each group were obtained by microscopy 2, 8 and 16 h after the cells were scratched (magnification, ×40). The extension of cells in the SPAG4-RNAi group was slower than those in the control. The line chart corresponds to the mean ± SEM, and the P-value was calculated using the Student\'s t-test. \*P\<0.05. SPAG4, sperm-associated antigen 4.](OR-40-02-0783-g02){#f3-or-40-02-0783}

![Subcellular localization of SPAG4 and its fragments in A549 cells. (A) Schematic diagram of the three domains of the SPAG4 protein. Different recombinational fragments of SPAG4 were designed to study its function. (B) Plasmids of different SPAG4 fragments were electrically transfected into A549 cells, and the fluorescence distribution was observed under a confocal laser scanning microscope (magnification, ×600). SPAG4, sperm-associated antigen 4.](OR-40-02-0783-g03){#f4-or-40-02-0783}

![SPAG4 interacts with Nesprin3 in the nuclear envelope. (A) Co-IP of FLAG-SPAG4 with HA-Nesprin3. The lysates of A549 cells co-transfected with the FLAG-SPAG4 and HA-Nesprin3 vectors were subjected to IP as observed in the right panel with an anti-FLAG antibody (lane 3, left), an anti-HA antibody (lane 3, right) or a non-specific control IgG (lane 2) and IB with an anti-HA or anti-FLAG antibody. An input protein (5%) was used as the control in the IB of the transfected cell lysates (lane 1). (B) The BiFC assay. Cells transfected with SPAG4-YC or Nesprin3-YN alone which acted as control groups exhibited no fluorescence. When SPAG4-YC and Nesprin3-YN plasmids were co-transfected into cells, the YC and YN fragments at the ends were complementary and exhibited yellow fluorescence. It is evident that SPAG4 and Nesprin3 interacted with each other around the nuclear envelope. SPAG4, sperm-associated antigen 4; Co-IP, co-immunoprecipitation; IB, immunoblotted; BiFC, bimolecular fluorescence complementation.](OR-40-02-0783-g04){#f5-or-40-02-0783}

![SPAG4 silencing inhibits the distribution and expression of Nesprin3 in lung cancer cells. (A) Nesprin3 localization in SPAG4-RNAi-treated A549 cells and control A549 cells, is displayed using Cy3 red fluorescence-labeled Nesprin3 antibody. (B and C) Protein levels of Nesprin3 and SPAG4 were determined in SPAG4-RNAi-treated A549 cells and control cells using western blotting, respectively. GAPDH was used as an internal control. The bars correspond to the mean ± SEM. The P-value was calculated using the Student\'s t-test. \*\*P\<0.01. SPAG4, sperm-associated antigen 4.](OR-40-02-0783-g05){#f6-or-40-02-0783}

![Effects of Nesprin3 gene silencing. (A) Western blotting results of Nesprin3 or GAPDH antibodies in control cells, Nesprin3 shRNA treated cells (N-3 RNAi\#1 and N-3 RNAi\#2) at 9 days after transfection with neomycin (1 mg/ml) screening. Unrelated bands are trimmed for space. (B and C) Gap closure was significantly suppressed by silencing Nesprin3, respectively (magnification, ×40). The bars correspond to the mean ± SEM. The P-value was calculated using the Student\'s t-test. \*P\<0.05. SPAG4, sperm-associated antigen 4.](OR-40-02-0783-g06){#f7-or-40-02-0783}

###### 

Differential expression of SPAG4 in cancerous and corresponding adjacent tissues.

                   SPAG4 expression        
  ----------- ---- ------------------ ---- -----------------------------------------------------
  Cancerous   46   14                 32   69.6^[a](#tfn1-or-40-02-0783){ref-type="table-fn"}^
  Adjacent    46   36                 10   21.7

The ratio of SPAG4 positivity was significantly different between the cancerous and adjacent tissues (P\<0.001). SPAG4, sperm-associated antigen 4.

###### 

Association between SPAG4 expression and clinicopathological features.

                                          SPAG4 expression                  
  ---------------------------------- ---- ------------------ --- ----- ---- ------------------------------------------------------
  Total                              46   5                  9   18    14   
  Age (years)                                                               0.403
    \<60                             22   4                  4     8   6    
    \>60                             24   1                  5   10    8    
  Histological type                                                         0.766
    Squamous carcinoma               15   1                  4     5   5    
    Adenocarcinoma                   31   4                  5   13    9    
  Tissue size (cm)                                                          0.447
    D\<3                             16   2                  4     6   4    
    D\>3                             30   3                  5   12    10   
  Clinical grade                                                            0.008^[a](#tfn2-or-40-02-0783){ref-type="table-fn"}^
    I                                17   3                  6     6   2    
    II                               16   2                  3     5   6    
    III                              13   0                  0     7   6    
  Differentiation degree                                                    0.014^[a](#tfn2-or-40-02-0783){ref-type="table-fn"}^
    Undifferentiated                 8    0                  0     3   5    
    Poorly differentiated            13   0                  2     5   6    
    Moderately/well-differentiated   25   5                  7   10    3    
  Lymph node metastasis                                                     0.035^[a](#tfn2-or-40-02-0783){ref-type="table-fn"}^
    Yes                              30   2                  4   13    11   
    No                               16   3                  5     5   3    

P\<0.05, significantly different. SPAG4, sperm-associated antigen 4.

[^1]: Contributed equally
